POS-285 EXPANDING THE POTENTIAL BENEFIT OF HYPOXIA-INDUCIBLE FACTOR PROLYL HYDROXYLASE INHIBITORS FOR IMPROVING DYSLIPIDEMIA IN ANEMIA OF CHRONIC KIDNEY DISEASE PATIENTS: META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Abstract

Anemia is one of the most prevalent complications in chronic kidney disease (CKD) patients and about 5-10% of the patients tend to develop erythropoiesis-stimulating agents (ESA) resistance. Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has shown efficacies in improving anemia and inflammation parameters in CKD patients. Some studies suggest that HIF-PHI also gives an improvement of lipid profiles in CKD patients, although the results are still inconclusive. This study aims to compare the treatment efficacies between HIF-PHI and ESA for improving dyslipidemia in anemia of CKD patients.